Jade Biosciences
JBIO
64 hedge funds and large institutions have $524M invested in Jade Biosciences in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 10 closing their positions.
0.19% less ownership
Funds ownership: 3.18% → 2.99% (-0.19%)
6% less funds holding
Funds holding: 68 → 64 (-4)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
35% less capital invested
Capital invested by funds: $803M → $524M (-$279M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.94M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.7M |
| 4 |
VA
VR Adviser
New York
|
+$2.04M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.37M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.36M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.51M |
| 5 |
Millennium Management
New York
|
-$2.43M |
JBIO Hedge Fund Activity: Q1 2023 in Review
64 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q1 2023, worth a combined $524M — down 35% from $803M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of JBIO and 6 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 22 added.
The largest buyer was Great Point Partners, adding an estimated $8.94M. The largest seller was Citadel Advisors, exiting entirely with an estimated $45.8M sold.
- 64 institutional investors held Jade Biosciences (JBIO) as of Q1 2023, down from 68 in Q4 2022.
- Funds reported $524M of Jade Biosciences stock for Q1 2023, down 35% quarter-over-quarter.
- 6 funds opened new Jade Biosciences positions in Q1 2023 and 10 closed out, a net change of -4 holders.
- The largest Jade Biosciences buyer in Q1 2023 was Great Point Partners, an estimated $8.94M added.
- The largest Jade Biosciences seller in Q1 2023 was Citadel Advisors, an estimated $45.8M sold.
Based on aggregated 13F filings for Q1 2023.